WO2003006689A3 - Diagnosis and treatment of diseases associated with altered expression of hipk1 - Google Patents

Diagnosis and treatment of diseases associated with altered expression of hipk1 Download PDF

Info

Publication number
WO2003006689A3
WO2003006689A3 PCT/EP2002/007854 EP0207854W WO03006689A3 WO 2003006689 A3 WO2003006689 A3 WO 2003006689A3 EP 0207854 W EP0207854 W EP 0207854W WO 03006689 A3 WO03006689 A3 WO 03006689A3
Authority
WO
WIPO (PCT)
Prior art keywords
hipk1
diagnosis
treatment
diseases associated
altered expression
Prior art date
Application number
PCT/EP2002/007854
Other languages
French (fr)
Other versions
WO2003006689A2 (en
Inventor
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Original Assignee
Univ Aarhus
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/029798 external-priority patent/WO2002024867A2/en
Application filed by Univ Aarhus, Finn Skou Pedersen, Annette Balle Sorensen, Javier Martin Hernandez filed Critical Univ Aarhus
Priority to CA002460642A priority Critical patent/CA2460642A1/en
Priority to EP02764693A priority patent/EP1419276A2/en
Priority to AU2002328896A priority patent/AU2002328896B2/en
Publication of WO2003006689A2 publication Critical patent/WO2003006689A2/en
Priority to US10/503,410 priority patent/US20070092873A1/en
Publication of WO2003006689A3 publication Critical patent/WO2003006689A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to methods using HIPK1 sequences for use in diagnosis and treatment of lymphoma and leukemia. In addition, the present invention describes the use of these compositions for use in screening methods.
PCT/EP2002/007854 2001-07-13 2002-07-15 Diagnosis and treatment of diseases associated with altered expression of hipk1 WO2003006689A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002460642A CA2460642A1 (en) 2001-07-13 2002-07-15 Diagnosis and treatment of diseases associated with altered expression of hipk1
EP02764693A EP1419276A2 (en) 2001-07-13 2002-07-15 Diagnosis and treatment of diseases associated with altered expression of hipk1
AU2002328896A AU2002328896B2 (en) 2001-07-13 2002-07-15 Diagnosis and treatment of diseases associated with altered expression of HIPK1
US10/503,410 US20070092873A1 (en) 2001-07-13 2003-07-02 Digital identification of genetic materials and methods for acquiring data for it

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90549101A 2001-07-13 2001-07-13
US09/905,491 2001-07-13
PCT/US2001/029798 WO2002024867A2 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
USPCT/US01/29798 2001-09-24

Publications (2)

Publication Number Publication Date
WO2003006689A2 WO2003006689A2 (en) 2003-01-23
WO2003006689A3 true WO2003006689A3 (en) 2003-08-07

Family

ID=26680574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/007854 WO2003006689A2 (en) 2001-07-13 2002-07-15 Diagnosis and treatment of diseases associated with altered expression of hipk1

Country Status (3)

Country Link
EP (1) EP1419276A2 (en)
AU (1) AU2002328896B2 (en)
WO (1) WO2003006689A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007215083A1 (en) * 2006-02-14 2007-08-23 President And Fellows Of Harvard College Mitotic progression genes and methods of modulating mitosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 July 1999 (1999-07-01), SHANG ET AL.: "Mus musculus protein kinase Myak-L (Myak) mRNA, alternatively spliced, complete cds", XP002242589, Database accession no. AF071070 *
DATABASE EMBL [online] 15 July 1998 (1998-07-15), ISHIKAWA ET AL.: "Homo sapiens mRNA for KIAA0630 protein, partial cds", XP002242590, Database accession no. AB014530 *
KIM ET AL: "Homeodomain-interacting Protein Kinases, a novel Family of Co-repressors", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 273, no. 40, 2 October 1998 (1998-10-02), pages 25875 - 25879, XP002208114, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2002328896B2 (en) 2008-01-24
WO2003006689A2 (en) 2003-01-23
EP1419276A2 (en) 2004-05-19

Similar Documents

Publication Publication Date Title
WO2003008583A3 (en) Novel compositions and methods for cancer
EP2014669A3 (en) Compositions and methods for cancer
WO2005027966A3 (en) Antibodies with altered effector functions
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2004006858A3 (en) Compounds, compositions, and methods employing same
IL173299A0 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
TW200510343A (en) Substituted dihydroquinazolines
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2005002526A3 (en) Method and compositions for treatment of viral infections
GB0111186D0 (en) Novel compounds
WO2003057146A3 (en) Novel compositions and methods for cancer
WO2004091490A3 (en) Somatostatin-dopamine chimeric analogs
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2002024867A3 (en) Novel compositions and methods for lymphoma and leukemia
WO2003045324A3 (en) 14-methyl-epothilones
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2003035837A3 (en) Novel compositions and methods for cancer
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2003039484A3 (en) Novel compositions and methods for cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002764693

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2460642

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002328896

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002764693

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2007092873

Country of ref document: US

Ref document number: 10503410

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10503410

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2002328896

Country of ref document: AU

Date of ref document: 20020715

Kind code of ref document: B